entacapone sold brand name comtan among others medication commonly used combination medications treatment parkinsons entacapone together levodopa carbidopa allows levodopa longer effect brain reduces parkinsons disease signs symptoms greater length time levodopa carbidopa therapy entacapone selective reversible inhibitor enzyme catecholomethyltransferase taken together levodopa ldopa carbidopa entacapone stops catecholomethyltransferase breaking metabolizing levodopa resulting overall increase levodopa remaining brain carbidopalevodopaentacapone stalevo medication developed orion pharma marketed novartis single tablet formulation contains levodopa carbidopa entacapone used addition levodopa carbidopa people parkinsons disease treat signs symptoms endofdose wearingoff characterized reappearance motor nonmotor symptoms parkinsons disease occurring towards end previous levodopa carbidopa clinical trials entacapone shown slow progression reverse parkinsons entacapone orally active drug taken without pregnancy category c risk ruled although animal studies showed entacapone excreted maternal rat milk studies human breast milk caution advised mothers taking entacapone breastfeeding entacapone safety efficacy assessed infants biliary excretion major route excretion entacapone people liver dysfunction may require additional caution frequent liver function monitoring taking significant considerations people poor kidney function taking high risk allergic reactions people hypersensitive potential limiting conditions consider starting entacapone following side effects reported people parkinsons disease treated entacapone common side effect entacapone movement problems occur people taking drug may cause worsen dyskinesia people parkinsons disease treated together levodopa particular peakdose dyskinesias may occur levodopa levels peak concentration serum patients taking entacapone shown experience diarrhea may occur within weeks initial entacapone use resolves discontinuation drug use entacapone presence diarrhea also associated weight loss low potassium levels clinical studies severe diarrhea common reason discontinuation people taking entacapone experience change urine color orange red brown black side effect due entacapone metabolism excretion urine shown people reported sudden sleep onset engaging daily activities without prior warning drowsiness controlled studies patients entacapone increased risk somnolence compared episodes orthostatic hypotension shown common start entacapone use due increased levels postmarketing data shows entacapone may change worsen mental status leading behaviors delusions agitation confusion people taking entacapone may experience increased urges participate gambling sexual activities money spending stimulating reward studies entacapone shown low potential interaction drugs theory could interact mao inhibitors tricyclic antidepressants noradrenaline reuptake inhibitors also increase catecholamine levels body drugs metabolized comt example methyldopa dobutamine apomorphine adrenaline isoprenaline iron could form chelates substances binding albumin site blood plasma example diazepam ibuprofen drugs metabolized liver enzyme example warfarin none medications tested studies shown clinically relevant interactions except perhaps warfarin increase inr seen combined entacapone selective reversible inhibitor catecholomethyltransferase comt eliminates biologically active catechols present catecholamines dopamine norepinephrine epinephrine hydroxylated metabolites administered decarboxylase inhibitor comt acts major metabolizing enzyme levodopa metabolizes brain treatment parkinsons disease entacapone given adjunct levodopa aromatic amino acid decarboxylase inhibitor carbidopa entacapone inhibits comt periphery marginally metabolism levodopa thus increasing plasma levels levodopa causing constant dopaminergic stimulation order reduce signs symptoms presented time highest blood plasma concentrations approximately one hour substance undergoes extensive firstpass metabolism absolute oral bioavailability f volume distribution vd intravenous injection approximately liters circulating entacapone bound serum albumin limits distribution entacapone primarily metabolized glucuronide liver converted halflife approximately hours excreted unchanged httpsenwikipediaorgwikientacapone